407 related articles for article (PubMed ID: 25141905)
1. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
[TBL] [Abstract][Full Text] [Related]
2. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.
Ross J; Jiamsakul A; Kumarasamy N; Azwa I; Merati TP; Do CD; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Ng OT; Choi JY; Oka S; Sohn AH; Law M
HIV Med; 2021 Mar; 22(3):201-211. PubMed ID: 33151020
[TBL] [Abstract][Full Text] [Related]
3. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Defo VF; Moudourou S; Fokam J; Kouanfack C; Torimiro J
J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
[TBL] [Abstract][Full Text] [Related]
4. Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
Johnston V; Cohen K; Wiesner L; Morris L; Ledwaba J; Fielding KL; Charalambous S; Churchyard G; Phillips A; Grant AD
J Infect Dis; 2014 Mar; 209(5):711-20. PubMed ID: 23943851
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
[TBL] [Abstract][Full Text] [Related]
7. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.
Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; de Wit TF;
J Acquir Immune Defic Syndr; 2011 Sep; 58(1):23-31. PubMed ID: 21694603
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chantratita W
Curr HIV Res; 2008 Sep; 6(5):474-6. PubMed ID: 18855659
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
[TBL] [Abstract][Full Text] [Related]
10. High Prevalence of Drug Resistance Mutations Among Patients Failing First-Line Antiretroviral Therapy and Predictors of Virological Response 24 Weeks After Switch to Second-Line Therapy in São Paulo State, Brazil.
Matsuda EM; Coelho LPO; Romero GF; de Moraes MJ; Lopez-Lopes GIS; Morejon K; Campeas AE; Cabral GB; Brígido LFM
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):156-164. PubMed ID: 28969448
[TBL] [Abstract][Full Text] [Related]
11. High turnaround times and low viral resuppression rates after reinforced adherence counselling following a confirmed virological failure diagnostic algorithm in HIV-infected patients on first-line antiretroviral therapy from Tanzania.
Kroidl A; Burger T; Urio A; Mugeniwalwo R; Mgaya J; Mlagalila F; Hoelscher M; Däumer M; Salehe O; Sangare A; Lennemann T; Maganga L
Trop Med Int Health; 2020 May; 25(5):579-589. PubMed ID: 31984634
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
13. Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
Karade SK; Ghate MV; Chaturbhuj DN; Kadam DB; Shankar S; Gaikwad N; Gurav S; Joshi R; Sane SS; Kulkarni SS; Kurle SN; Paranjape RS; Rewari BB; Gangakhedkar RR
Medicine (Baltimore); 2016 Sep; 95(37):e4886. PubMed ID: 27631260
[TBL] [Abstract][Full Text] [Related]
14. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC
J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546
[TBL] [Abstract][Full Text] [Related]
15. Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
Prasitsuebsai W; Teeraananchai S; Singtoroj T; Truong KH; Ananworanich J; Do VC; Nguyen LV; Kosalaraksa P; Kurniati N; Sudjaritruk T; Chokephaibulkit K; Kerr SJ; Sohn AH
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):380-6. PubMed ID: 27355415
[TBL] [Abstract][Full Text] [Related]
16. Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
Shafran SD; Hughes CA
HIV Med; 2023 Mar; 24(3):361-365. PubMed ID: 35973753
[TBL] [Abstract][Full Text] [Related]
17. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
Sigaloff KC; Kayiwa J; Musiime V; Calis JC; Kaudha E; Mukuye A; Matama C; Nankya I; Nakatudde L; Dekker JT; Hamers RL; Mugyenyi P; Rinke De Wit TF; Kityo C
AIDS Res Hum Retroviruses; 2013 Jun; 29(6):925-30. PubMed ID: 23517497
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study.
Karade SK; Kulkarni SS; Ghate MV; Patil AA; Londhe R; Salvi SP; Kadam DB; Joshi RK; Rewari BB; Gangakhedkar RR
PLoS One; 2017; 12(8):e0181889. PubMed ID: 28763465
[TBL] [Abstract][Full Text] [Related]
19. Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.
Aghokeng AF; Kouanfack C; Eymard-Duvernay S; Butel C; Edoul GE; Laurent C; Koulla-Shiro S; Delaporte E; Mpoudi-Ngole E; Peeters M
J Int AIDS Soc; 2013 Jan; 16(1):18004. PubMed ID: 23374858
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 drug resistance testing at second-line regimen failure in Arua, Uganda: avoiding unnecessary switch to an empiric third-line.
Fily F; Ayikobua E; Ssemwanga D; Nicholas S; Kaleebu P; Delaugerre C; Pasquier E; Amoros Quiles I; Balkan S; Schramm B
Trop Med Int Health; 2018 Oct; 23(10):1075-1083. PubMed ID: 30058269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
